These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 10961607)

  • 1. Intravenous drug use, relationship with providers, and stage of HIV disease influence the prescription rates of protease inhibitors.
    Murri R; Fantoni M; Del Borgo C; Izzi I; Visonà R; Suter F; Banfi MC; Barchi E; Orchi N; Bosco O; Wu AW
    J Acquir Immune Defic Syndr; 1999 Dec; 22(5):461-6. PubMed ID: 10961607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study.
    Bassetti S; Battegay M; Furrer H; Rickenbach M; Flepp M; Kaiser L; Telenti A; Vernazza PL; Bernasconi E; Sudre P
    J Acquir Immune Defic Syndr; 1999 Jun; 21(2):114-9. PubMed ID: 10360802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Self-reported antiretroviral therapy in injection drug users.
    Celentano DD; Vlahov D; Cohn S; Shadle VM; Obasanjo O; Moore RD
    JAMA; 1998 Aug; 280(6):544-6. PubMed ID: 9707145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of injecting drug use on response to highly active antiretroviral treatment in HIV-1-infected patients: a nationwide population-based cohort study.
    Larsen MV; Omland LH; Gerstoft J; Røge BT; Larsen CS; Pedersen G; Obel N; Kronborg G
    Scand J Infect Dis; 2010 Dec; 42(11-12):917-23. PubMed ID: 20840000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
    Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
    J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in cellular activation and apoptosis in HIV-infected patients receiving protease inhibitors or nonnucleoside reverse transcriptase inhibitors.
    Benito JM; López M; Martín JC; Lozano S; Martínez P; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2002 Dec; 18(18):1379-88. PubMed ID: 12487809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Access to antiretroviral treatment among French HIV infected injection drug users: the influence of continued drug use. MANIF 2000 Study Group.
    Carrieri MP; Moatti JP; Vlahov D; Obadia Y; Reynaud-Maurupt C; Chesney M
    J Epidemiol Community Health; 1999 Jan; 53(1):4-8. PubMed ID: 10326045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Barriers to use of free antiretroviral therapy in injection drug users.
    Strathdee SA; Palepu A; Cornelisse PG; Yip B; O'Shaughnessy MV; Montaner JS; Schechter MT; Hogg RS
    JAMA; 1998 Aug; 280(6):547-9. PubMed ID: 9707146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
    Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
    JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/microL).
    Floridia M; Bucciardini R; Fragola V; Galluzzo CM; Giannini G; Pirillo MF; Amici R; Andreotti M; Ricciardulli D; Tomino C; Vella S;
    HIV Med; 2004 Jan; 5(1):1-10. PubMed ID: 14731162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies.
    Wood E; Hogg RS; Heath KV; de la Rosa R; Lee N; Yip B; O'Shaughnessy MV; Montaner JS
    AIDS; 2003 Dec; 17(18):2629-34. PubMed ID: 14685057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of efavirenz as a part of late rescue antiretroviral treatment.
    Manfredi R; Rizzo E; Calza L; Chiodo F
    HIV Clin Trials; 2001; 2(5):413-20. PubMed ID: 11673816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in prescriptions for highly active antiretroviral therapy in four New York City HIV clinics.
    Sackoff JE; McFarland JW; Shin SS
    J Acquir Immune Defic Syndr; 2000 Feb; 23(2):178-83. PubMed ID: 10737433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.
    Lima VD; Gill VS; Yip B; Hogg RS; Montaner JS; Harrigan PR
    J Infect Dis; 2008 Jul; 198(1):51-8. PubMed ID: 18498238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protease inhibitor combination therapy, severity of illness, and quality of life among children with perinatally acquired HIV-1 infection.
    Storm DS; Boland MG; Gortmaker SL; He Y; Skurnick J; Howland L; Oleske JM;
    Pediatrics; 2005 Feb; 115(2):e173-82. PubMed ID: 15629958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
    Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
    Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care?
    Mocroft A; Gill MJ; Davidson W; Phillips AN
    J Acquir Immune Defic Syndr; 2000 Aug; 24(5):475-82. PubMed ID: 11035619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in prescription of antiretroviral therapy in a large cohort of HIV-infected patients.
    McNaghten AD; Hanson DL; Dworkin MS; Jones JL;
    J Acquir Immune Defic Syndr; 2003 Apr; 32(5):499-505. PubMed ID: 12679701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting.
    Siripassorn K; Manosuthi W; Chottanapund S; Pakdee A; Sabaitae S; Prasithsirikul W; Tunthanathip P; Ruxrungtham K;
    AIDS Res Hum Retroviruses; 2010 Feb; 26(2):139-48. PubMed ID: 20156097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.